Lazor Romain, Valeyre Dominique, Lacronique Jacques, Wallaert Benoît, Urban Thierry, Cordier Jean-François
Division de Pneumologie, Hôpitaux Universitaires, 24, rue Micheli-du-Crest, 1211 Genève 14, Switzerland.
Respir Med. 2004 Jun;98(6):536-41. doi: 10.1016/j.rmed.2003.11.013.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare interstitial disorder affecting exclusively women, and leading to progressive deterioration of lung function. The disease course is highly variable from one patient to another, but no clinical predictor of rapid disease progression is currently available. To identify clinical variables, which could detect patients at risk for rapid lung function decline, we searched for correlations between the rate of forced expiratory volume in 1 s (FEV1) decline and clinical features at diagnosis in a retrospective series of 31 cases of LAM followed for > or = 1 yr. The mean FEV1 decline was 106+/-143 ml/yr or 3.4+/-4.6% predicted FEV1/yr. Among clinical features at diagnosis, only initial values of carbon monoxide transfer factor (TLCO, P = 0.006) and carbon monoxide transfer coefficient (KCO, P = 0.0001) were significantly correlated with the rate of FEV1 decline. Lung volumes and FEV1/forced vital capacity ratio at diagnosis were not predictive of rapid decline. No effect of previous smoking, contraceptive use or pregnancy on FEV1 decline could be detected. We conclude that low TLCO and KCO at the time of diagnosis are the best clinical predictors of rapid FEV1 decline in patients with LAM.
肺淋巴管平滑肌瘤病(LAM)是一种罕见的间质性疾病,仅影响女性,并导致肺功能进行性恶化。不同患者的病程差异很大,但目前尚无快速疾病进展的临床预测指标。为了确定能够检测出有肺功能快速下降风险的患者的临床变量,我们在一组31例随访时间≥1年的LAM患者回顾性系列研究中,寻找1秒用力呼气量(FEV1)下降率与诊断时临床特征之间的相关性。FEV1的平均下降率为106±143ml/年或预测FEV1的3.4±4.6%/年。在诊断时的临床特征中,只有一氧化碳弥散量(TLCO,P = 0.006)和一氧化碳弥散系数(KCO,P = 0.0001)的初始值与FEV1下降率显著相关。诊断时的肺容积和FEV1/用力肺活量比值不能预测快速下降。未检测到既往吸烟、使用避孕药或怀孕对FEV1下降有影响。我们得出结论,诊断时低TLCO和KCO是LAM患者FEV1快速下降的最佳临床预测指标。